CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.

Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial

Open access

Abstract

Objective To date, treatment options (i.e. psychotherapy, antidepressant medications) for patients with posttraumatic stress disorder (PTSD), are relatively few, and considering their limited efficacy, novel therapies have gained interest among researchers and treatment providers alike. Among patients with chronic pain (CP) about one third experience comorbid PTSD, which further complicates their already challenging pharmacological regimens. Low dose ketamine infusion has shown promise in PTSD, and in treatment of CP, however they have not been studied in comorbid population and under rigorous control conditions. Methods We compared the effects of a single dose of either ketamine (0.5 mg/kg) or ketorolac (15 mg) over a 40-minute of IV infusion in CP patients with and without PTSD, in double blind, randomized study. Measures were collected before, during, one day and seven days after the infusion. A planned sample size of 40 patients randomly assigned to treatment order was estimated to provide 80% power to detect a hypothesized treatment difference after the infusion. Main Outcome and Measures: The primary outcome measures were change in PTSD symptom severity assessed with the Impact of Event Scale–Revised (IES-R) and Visual Analogue Scale (VAS) for pain administered by a study clinician 24 hours post infusion. Secondary outcome measures included Impact of Event Scale–Revised (IES-R), VAS and Brief Pain Inventory (Short Form) for pain 1 week after the infusion. Results Both treatments offered comparable improvement of PTSD and CP symptoms that persisted for 7 days after the infusion. Patients with comorbid PTSD and CP experienced less dissociative side effects compared to the CP group. Surprisingly, ketorolac infusion resulted in dissociative symptoms in CP patients only. Conclusions This first prospective study comparing effects of subanesthetic ketamine versus ketorolac infusions for comorbid PTSD and CP, suggests that both ketamine and ketorolac might offer meaningful and durable response for both PTSD and CP symptoms.

Overview

CoChat Summary

## TL;DR

This randomized double-blind clinical trial found that single low-dose infusions of ketamine and ketorolac produced comparable improvements in PTSD and chronic pain symptoms over 7 days in veterans with chronic pain, including those with comorbid PTSD. The study also reported fewer dissociative side effects in the comorbid PTSD+chronic pain group than in chronic pain alone, and unexpectedly saw dissociative symptoms with ketorolac in chronic pain patients.

## Key findings

  • 41 participants were randomized after 48 completed consent; participants were ages 29 to 65.
  • In the CP+PTSD group, PTSD symptoms decreased significantly from baseline to 7 days post-infusion in both medication groups (F(1, 52) = 9.35, p < 0.01), with significant decreases at 1 day (t(32.59)=2.33, p = 0.03) and 7 days (t(27.53)=2.93, p < 0.01); there was no significant medication effect.
  • For pain, there were significant immediate effects on VAS of medication (F(1,148)=14.69, p<0.001) and time (F(1,148)=26.55, p<0.001); in the CP group, ketamine had lower pain scores than ketorolac (M = 26.78 vs 52.2; t(74)=2.18, p < 0.001).
  • On the BPI pain scale, pain and interference scores changed over time, with group-by-medication interactions; in the CP group, ketorolac was associated with greater pain than ketamine (M = 21.17 vs 16.61; t(69.9)=2.14, p = 0.035), and for pain interference the CP group also showed ketorolac > ketamine (M = 28.25 vs 18.05; t(70.6)=2.5, p = 0.01).
  • Dissociative symptoms differed by diagnosis and medication: in the CP group, ketamine had greater dissociative symptom endorsement than ketorolac (M = 4.45 vs 0.53; t(88.4) = -3.98, p < 0.001), while the CP+PTSD group showed no significant ketamine-ketorolac difference.

## Methods

  • Design: Outpatient randomized, double-blind clinical trial comparing a single 40-minute IV infusion of ketamine (0.5 mg/kg) versus ketorolac (15 mg); participants and staff were blinded except the anesthesiologist.
  • Sample/data: 41 eligible participants from the Ann Arbor VA outpatient pain clinic (enrolled January 2018 to June 2019), ages 18 to 65, divided into chronic pain only vs chronic pain + PTSD groups; all were veterans per the study’s framing.
  • Analysis: Repeated-measures ANOVAs assessed changes in PTSD symptoms, pain, dissociation, and side effects across baseline and follow-up time points; Bonferroni corrections were used for multiple tests.

## Limitations

  • The paper explicitly states that group sizes were very modest, so findings need replication in larger cohorts.
  • The paper explicitly notes the lack of an inactive placebo (normal saline) control and says this limits interpretation; it also says including a PTSD-without-chronic-pain group would better isolate medication effects.
  • The paper explicitly says it does not address depression or suicidal ideation (suicidal ideation was an exclusion criterion), limiting assessment of broader therapeutic benefit.
  • Evident from the text: the study’s outcomes were followed only to 7 days, so it cannot establish longer-term durability beyond one week.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/2470547020981670

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1. Consolidated standards of reporting trials patient flowchart.
Figure 1. Consolidated standards of reporting trials patient flowchart.CC BY-NC · PubMed Central
Figure 2. Change in the Impact of Event Scale-Revised (IES-R) total score over 1 week. Error bars represent standard deviation.
Figure 2. Change in the Impact of Event Scale-Revised (IES-R) total score over 1 week. Error bars represent standard deviation.CC BY-NC · PubMed Central
Figure 3. Change in Visual Analogue Scale (VAS) over 1 week. Error bars represent standard deviation.
Figure 3. Change in Visual Analogue Scale (VAS) over 1 week. Error bars represent standard deviation.CC BY-NC · PubMed Central
Figure 4. Change in brief Pain Inventory Pain Intensity scale over 1 week. Error bars represent standard deviation.
Figure 4. Change in brief Pain Inventory Pain Intensity scale over 1 week. Error bars represent standard deviation.CC BY-NC · PubMed Central
Figure 5. Change in brief Pain Inventory Pain Interference scale over 1 week. Error bars represent standard deviation.
Figure 5. Change in brief Pain Inventory Pain Interference scale over 1 week. Error bars represent standard deviation.CC BY-NC · PubMed Central
Figure 6. Change in Clinician-Administered Dissociative States Scale (CADSS) score over 1 week. Error bars represent standard deviation.
Figure 6. Change in Clinician-Administered Dissociative States Scale (CADSS) score over 1 week. Error bars represent standard deviation.CC BY-NC · PubMed Central
Figure 7. Change in Patient Related Inventory of Side Effects (PRISE) score over 1 week. Error bars represent standard deviation. Both ketamine and ketorolac infusion were generally well tolerated by the patients in chronic pain and PTSD-chronic pain groups.
Figure 7. Change in Patient Related Inventory of Side Effects (PRISE) score over 1 week. Error bars represent standard deviation. Both ketamine and ketorolac infusion were generally well tolerated by the patients in chronic pain and PTSD-chronic pain groups.CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 13 Not checked · 59 Own results and interpretations

26 more claims

Create a free account to see all 72 claims and to verify the 19 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 40 references

Research works printed but not linked: 3

  1. Bosco MA, 2013, Pain Res Treat, 2013, 174728
  2. Cleeland CS, 1994, Ann Acad Med Singap, 23, 129
  3. Womble AL., 2013, AANA J, 81, 118

Cited by

See all 38

Metadata

Authors
Dadabayev, A. R., Joshi, S. A., Reda, M. H., Lake, T., Hausman, M. S., Domino, E., & Liberzon, I.
Affiliations
  • VA Ann Arbor Healthcare System (US)
  • University of Michigan (US)
  • Wayne State University (US)
  • Texas A&M University (US)
Corresponding author
Dadabayev, Alisher R.
Venue
Chronic Stress
Published
2020-01
Volume
4
Pages
2470547020981670-2470547020981670
ISSN
2470-5470 (ISSN-L)
OpenAlex
W3114255450
Cited by
37
References
40
Citations by year
2026: 3 · 2025: 7 · 2024: 10 · 2023: 11 · 2022: 5 · 2021: 1
FWCI
1.70
Type
journal article
Language
en
Open access
Locations
  • Chronic Stress (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
Keywords
ketamine infusion, ketorolac, post-traumatic stress disorder, chronic pain, low-dose ketamine, analgesic effect, Impact of Event Scale

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial. https://app.cochat.ai/papers/10.1177/2470547020981670
The paper
Dadabayev, A. R., Joshi, S. A., Reda, M. H., Lake, T., Hausman, M. S., Domino, E., & Liberzon, I. (2020). Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial. Chronic Stress. https://doi.org/10.1177/2470547020981670

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.